How medical choices influence quality of life of women carrying a BRCA mutation

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 3, 2015, Pages 555-568

  Harmsen, Marline G ^a   Hermens, Rosella P M G ^a   Prins, Judith B ^a   Hoogerbrugge, Nicoline ^a   de Hullu, Joanne A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BRCA; HRT; Menopause; Quality of life; Risk reducing mastectomy; Risk reducing salpingo oophorectomy

Indexed keywords

ANXIETY DISORDER; BODY IMAGE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; DISTRESS SYNDROME; FOLLOW UP; GERMLINE MUTATION; HUMAN; MENOPAUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PATIENT WORRY; POSTOPERATIVE CARE; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK FACTOR; RISK REDUCTION; SALPINGOOOPHORECTOMY; SEXUALITY; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; FEMALE; GENETICS; HORMONE SUBSTITUTION; MASTECTOMY; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; PATIENT PREFERENCE; PSYCHOLOGY;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HORMONE REPLACEMENT THERAPY; HUMANS; MASTECTOMY; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; PATIENT PREFERENCE; QUALITY OF LIFE; RISK FACTORS;

EID: 84983142975     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.07.010     Document Type: Review

References (64)

1. Aaronson N.K. Quality of life: what is it? How should it be measured?. Oncology (Williston Park) 1988, 2:69-76. 64.
2. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 2003, 72:1117-1130.
3. Arts-de Jong M., Maas A.H., Massuger L.F., Hoogerbrugge N., de Hullu J.A. BRCA1/2 mutation carriers are potentially at higher cardiovascular risk. Crit. Rev. Oncol. Hematol. 2014, 9:159-171.
4. Atsma F., Bartelink M.L., Grobbee D.E., van der Schouw Y.T. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006, 13:265-279.
5. Barofsky I. Can quality or quality-of-life be defined?. Qual. Life Res. 2012, 21:625-631.
6. Beattie M.S., Crawford B., Lin F., Vittinghoff E., Ziegler J. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet. Test. Mol. Biomarkers 2009, 13:51-56.
7. Beran T.M., Stanton A.L., Kwan L., Seldon J., Bower J.E., Vodermaier A., et al. The trajectory of psychological impact in BRCA1/2 genetic testing: does time heal?. Ann. Behav. Med. 2008, 36:107-116.
8. Bordeleau L., Panchal S., Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res. Treat. 2010, 119:13-24.
9. Brandberg Y., Arver B., Lindblom A., Sandelin K., Wickman M., Hall P. Preoperative psychological reactions and quality of life among women with an increased risk of breast cancer who are considering a prophylactic mastectomy. Eur. J. Cancer 2004, 40:365-374.
10. Brandberg Y., Sandelin K., Erikson S., Jurell G., Liljegren A., Lindblom A., et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J. Clin. Oncol. 2008, 26:3943-3949.
11. Bresser P.J., Seynaeve C., Van Gool A.R., Niermeijer M.F., Duivenvoorden H.J., van Dooren S., et al. The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy. Eur. J. Cancer 2007, 43:95-103.
12. Bresser P.J., Van Gool A.R., Seynaeve C., Duivenvoorden H.J., Niermeijer M.F., van Geel A.N., et al. Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy?. Ann. Oncol. 2007, 18:1641-1645.
13. Chapman J.S., Powell C.B., McLennan J., Crawford B., Mak J., Stewart N., et al. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers. Gynecol. Oncol. 2011, 122:339-343.
14. Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007, 25:1329-1333.
15. Claes E., Evers-Kiebooms G., Denayer L., Decruyenaere M., Boogaerts A., Philippe K., et al. Predictive genetic testing for hereditary breast and ovarian cancer: psychological distress and illness representations 1 year following disclosure. J. Genet. Couns. 2005, 14:349-363.
16. den Heijer M., Seynaeve C., Timman R., Duivenvoorden H.J., Vanheusden K., Tilanus-Linthorst M., et al. Body image and psychological distress after prophylactic mastectomy and breast reconstruction in genetically predisposed women: a prospective long-term follow-up study. Eur. J. Cancer 2012, 48:1263-1268.
17. den Heijer M., Seynaeve C., Vanheusden K., Timman R., Duivenvoorden H.J., Tilanus-Linthorst M., et al. Long-term psychological distress in women at risk for hereditary breast cancer adhering to regular surveillance: a risk profile. Psychooncology 2013, 22:598-604.
18. Domchek S.M., Friebel T.M., Singer C.F., Evans D.G., Lynch H.T., Isaacs C., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304:967-975.
19. Dowdy S.C., Stefanek M., Hartmann L.C. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy. Am. J. Obstet. Gynecol. 2004, 191:1113-1123.
20. Draycott S., Dabbs A. Cognitive dissonance. 1: An overview of the literature and its integration into theory and practice in clinical psychologypsychology. Br. J. Clin. Psychol. 1998, 37(Pt 3):341-353.
21. Fang C.Y., Cherry C., Devarajan K., Li T., Malick J., Daly M.B. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol. Oncol. 2009, 112:594-600.
22. Finch A., Metcalfe K.A., Chiang J.K., Elit L., McLaughlin J., Springate C., et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol. Oncol. 2011, 121:163-168.
23. Finch A., Metcalfe K.A., Chiang J., Elit L., McLaughlin J., Springate C., et al. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology 2013, 22:212-219.
24. Foster C., Watson M., Eeles R., Eccles D., Ashley S., Davidson R., et al. Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. Br. J. Cancer 2007, 96:718-724.
25. Gopie J.P., Mureau M.A., Seynaeve C., Ter Kuile M.M., Menke-Pluymers M.B., Timman R., et al. Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer. Fam. Cancer 2013, 12:479-487.
26. Hallowell N., Baylock B., Heiniger L., Butow P.N., Patel D., Meiser B., et al. Looking different, feeling different: women's reactions to risk-reducing breast and ovarian surgery. Fam. Cancer 2012, 11:215-224.
27. Hartmann L.C., Sellers T.A., Schaid D.J., Frank T.S., Soderberg C.L., Sitta D.L., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl. Cancer Inst. 2001, 93:1633-1637.
28. Heemskerk-Gerritsen B.A., Menke-Pluijmers M.B., Jager A., Tilanus-Linthorst M.M., Koppert L.B., Obdeijn I.M., et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann. Oncol. 2013, 24:2029-2035.
29. Howard-Anderson J., Ganz P.A., Bower J.E., Stanton A.L. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J. Natl. Cancer Inst. 2012, 104:386-405.
30. Isern A.E., Tengrup I., Loman N., Olsson H., Ringberg A. Aesthetic outcome, patient satisfaction, and health-related quality of life in women at high risk undergoing prophylactic mastectomy and immediate breast reconstruction. J. Plast. Reconstr. Aesthet. Surg. 2008, 61:1177-1187.
31. Lodder L.N., Frets P.G., Trijsburg R.W., Meijers-Heijboer E.J., Klijn J.G., Seynaeve C., et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res. Treat. 2002, 73:97-112.
32. Madalinska J.B., Hollenstein J., Bleiker E., van Beurden M., Valdimarsdottir H.B., Massuger L.F., et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J. Clin. Oncol. 2005, 23:6890-6898.
33. Madalinska J.B., van Beurden M., Bleiker E.M., Valdimarsdottir H.B., Hollenstein J., Massuger L.F., et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J. Clin. Oncol. 2006, 24:3576-3582.
34. Marchetti C., De Felice F., Palaia I., Perniola G., Musella A., Musio D., et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health 2014, 14:150.
35. Meijers-Heijboer H., van Geel B., van Putten W.L., Henzen-Logmans S.C., Seynaeve C., Menke-Pluymers M.B., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2001, 345:159-164.
36. Meiser B., Butow P., Friedlander M., Schnieden V., Gattas M., Kirk J., et al. Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J. Clin. Oncol. 2000, 18:2250-2257.
37. Meiser B., Butow P., Friedlander M., Barratt A., Schnieden V., Watson M., et al. Psychological impact of genetic testing in women from high-risk breast cancer families. Eur. J. Cancer 2002, 38:2025-2031.
38. Metcalfe K.A., Esplen M.J., Goel V., Narod S.A. Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. Psychooncology 2004, 13:14-25.
39. Metcalfe K.A., Esplen M.J., Goel V., Narod S.A. Predictors of quality of life in women with a bilateral prophylactic mastectomy. Breast J. 2005, 11:65-69.
40. Metcalfe K.A., Lubinski J., Ghadirian P., Lynch H., Kim-Sing C., Friedman E., et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J. Clin. Oncol. 2008, 26:1093-1097.
41. Michelsen T.M., Dorum A., Dahl A.A. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer. Gynecol. Oncol. 2009, 113:128-133.
42. Michelsen T.M., Dorum A., Trope C.G., Fossa S.D., Dahl A.A. Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer. Int. J. Gynecol. Cancer 2009, 19:1029-1036.
43. Mols F., Vingerhoets A.J., Coebergh J.W., van de Poll-Franse L.V. Quality of life among long-term breast cancer survivors: a systematic review. Eur. J. Cancer 2005, 41:2613-2619.
44. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J. Exp. Clin. Cancer Res. 2008, 27:32.
45. Nelson H.D., Fu R., Goddard K., Mitchell J.P., Okinaka-Hu L., Pappas M., et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the US Preventive Services Task Force Recommendation 2013, Rockville, MD.
46. O'Neill S.M., Rubinstein W.S., Sener S.F., Weissman S.M., Newlin A.C., West D.K., et al. Psychological impact of recall in high-risk breast MRI screening. Breast Cancer Res. Treat. 2009, 115:365-371.
47. Pezaro C., James P., McKinley J., Shanahan M., Young M.A., Mitchell G. The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause. Fam. Cancer 2012, 11:403-410.
48. Rebbeck T.R., Friebel T., Lynch H.T., Neuhausen S.L., van't Veer L., Garber J.E., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol. 2004, 22:1055-1062.
49. Rebbeck T.R., Kauff N.D., Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J. Natl. Cancer Inst. 2009, 101:80-87.
50. Rijnsburger A.J., Essink-Bot M.L., van Dooren S., Borsboom G.J., Seynaeve C., Bartels C.C., et al. Impact of screening for breast cancer in high-risk women on health-related quality of life. Br. J. Cancer 2004, 91:69-76.
51. Rocca W.A., Grossardt B.R., Maraganore D.M. The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener. Dis. 2008, 5:257-260.
52. Russo A., Calo V., Bruno L., Rizzo S., Bazan V., Di Fede G. Hereditary ovarian cancer. Crit. Rev. Oncol. Hematol. 2009, 69:28-44.
53. Shuster L.T., Gostout B.S., Grossardt B.R., Rocca W.A. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int. 2008, 14:111-116.
54. Singh K., Lester J., Karlan B., Bresee C., Geva T., Gordon O. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am. J. Obstet. Gynecol. 2013, 208:329. e1-6.
55. Spiegel T.N., Esplen M.J., Hill K.A., Wong J., Causer P.A., Warner E. Psychological impact of recall on women with BRCA mutations undergoing MRI surveillance. Breast 2011, 20:424-430.
56. Stan D.L., Shuster L.T., Wick M.J., Swanson C.L., Pruthi S., Bakkum-Gamez J.N. Challenging and complex decisions in the management of the BRCA mutation carrier. J. Womens Health (Larchmt) 2013, 22:825-834.
57. Svejme O., Ahlborg H.G., Nilsson J.A., Karlsson M.K. Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women. BJOG 2012, 119:810-816.
58. Touboul C., Uzan C., Ichante J.L., Caron O., Dunant A., Dauchy S., et al. Factors associated with altered long-term well-being after prophylactic salpingo-oophorectomy among women at increased hereditary risk for breast and ovarian cancer. Oncologist 2011, 16:1250-1257.
59. van Dooren S., Seynaeve C., Rijnsburger A.J., Duivenvoorden H.J., Essink-Bot M.L., Tilanus-Linthorst M.M., et al. Exploring the course of psychological distress around two successive control visits in women at hereditary risk of breast cancer. Eur. J. Cancer 2005, 41:1416-1425.
60. van Oostrom I., Meijers-Heijboer H., Lodder L.N., Duivenvoorden H.J., van Gool A.R., Seynaeve C., et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J. Clin. Oncol. 2003, 21:3867-3874.
61. van't Spijker A., ten Kroode H.F. Psychological aspects of genetic counselling: a review of the experience with Huntington's disease. Patient Educ. Couns. 1997, 32:33-40.
62. Vencken P.M., Reitsma W., Kriege M., Mourits M.J., de Bock G.H., de Hullu J.A., et al. Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands. Ann. Oncol. 2013, 24:2036-2042.
63. Watson M., Foster C., Eeles R., Eccles D., Ashley S., Davidson R., et al. Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. Br. J. Cancer 2004, 91:1787-1794.
64. Wenzel L., Osann K., Lester J., Kurz R., Hsieh S., Nelson E.L., et al. Biopsychological stress factors in BRCA mutation carriers. Psychosomatics 2012, 53:582-590.